AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33334938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory care with a flutter valve (Pleural Vent or Atrium Pneumostat)
Number of subjects: 41
Study 33334938 — intervention group
Group type: COMPARATOR
Intervention: Standard care with chest tube and underwater seal
Number of subjects: 41
Study 33334938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory care with Pleural Vent (PV)
Number of subjects: 41
Study 33334938 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 41
Study 33334938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory care with Atrium Pneumostat (AP)
Number of subjects: 41
Study 36153456 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication + Thunder-fire moxibustion
Number of subjects: 60
Study 36153456 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 60
Study 32749999 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based assessment using CANTAB
Number of subjects: 51
Study 32749999 — intervention group
Group type: COMPARATOR
Intervention: Lab-based assessment using CANTAB
Number of subjects: 51
Study 33278290 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital placement of a balloon catheter
Number of subjects: 372
Study 33278290 — intervention group
Group type: COMPARATOR
Intervention: Sterile speculum method
Number of subjects: 372
Study 33278290 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 372
Study 33278290 — intervention group
Group type: COMPARATOR
Intervention: Sterile speculum group
Number of subjects: 372
Study 33401330 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel standard-dose (10 mg)
Number of subjects: 255
Study 33401330 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel de-escalation strategy (5 mg and PFT-guided)
Number of subjects: 255
Study 33327696 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 80
Study 33327696 — intervention group
Group type: COMPARATOR
Intervention: Baska mask
Number of subjects: 80
Study 35612640 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Employment Intervention (IPS-MA)
Number of subjects: 289
Study 35612640 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 289
Study 33627776 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal intervention
Number of subjects: 264
Study 33627776 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 264
Study 34789277 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) intervention
Number of subjects: 30
Study 34789277 — intervention group
Group type: COMPARATOR
Intervention: Self-directed condition (receipt of information on TASSH without PF)
Number of subjects: 30
Study 35618611 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based participatory care program
Number of subjects: 90
Study 35618611 — intervention group
Group type: COMPARATOR
Intervention: Increased family participation (control group)
Number of subjects: 90
Study 35618611 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 90
Study 33646192 — intervention group
Group type: EXPERIMENTAL
Intervention: DEBISim software simulation pipeline
Number of subjects: 0
Study 35958679 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg esketamine
Number of subjects: 105
Study 35958679 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg lidocaine
Number of subjects: 105
Study 35958679 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 105
Study 33653326 — intervention group
Group type: EXPERIMENTAL
Intervention: i-PRF
Number of subjects: 21
Study 33653326 — intervention group
Group type: COMPARATOR
Intervention: Control (no i-PRF)
Number of subjects: 21
Study 32653539 — intervention group
Group type: EXPERIMENTAL
Intervention: Text Messaging (TM)
Number of subjects: 646
Study 32653539 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Number of subjects: 646
Study 32653539 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EC)
Number of subjects: 646
Study 35947894 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restriction Interventions (CRI)
Number of subjects: 3037
Study 35947894 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 3037
Study 35947894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Interventions (including both CRI and MD)
Number of subjects: 3037
Study 33352584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (8 IU, self-administered up to thrice daily for 4 weeks)
Number of subjects: 38
Study 33352584 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 38
Study 33352584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32814684 — intervention group
Group type: EXPERIMENTAL
Intervention: nGBE (Ginkgo biloba extract with pinitol)
Number of subjects: 100
Study 32814684 — intervention group
Group type: EXPERIMENTAL
Intervention: tGBE (traditional Ginkgo biloba extract without pinitol)
Number of subjects: 100
Study 32814684 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 100
Study 32814684 — intervention group
Group type: EXPERIMENTAL
Intervention: pinitol alone
Number of subjects: 100
Study 33125189 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-1654 (100 mg, 300 mg intramuscular; 300 mg, 1000 mg, 3000 mg intravenous)
Number of subjects: 152
Study 33125189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 32533791 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg.kg‐1 intranasal dexmedetomidine
Number of subjects: 247
Study 32533791 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 intravenous dexmedetomidine
Number of subjects: 247
Study 32533791 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 247
Study 35941557 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic guided internet-delivered intervention with synchronous assistance
Number of subjects: 207
Study 35941557 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic self-guided internet-delivered intervention
Number of subjects: 207
Study 35941557 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 207
Study 34016947 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (EcologicBarrier consisting of Lactobacilli, Lactococci, and Bifidobacteria)
Number of subjects: 56
Study 34016947 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (EcologicBarrier)
Number of subjects: 56
Study 34016947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 35278766 — intervention group
Group type: EXPERIMENTAL
Intervention: dinutuximab/irinotecan
Number of subjects: 471
Study 35278766 — intervention group
Group type: COMPARATOR
Intervention: irinotecan
Number of subjects: 471
Study 35278766 — intervention group
Group type: COMPARATOR
Intervention: topotecan
Number of subjects: 471
Study 32325919 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Fructose Diet (LFD)
Number of subjects: 438
Study 32325919 — intervention group
Group type: COMPARATOR
Intervention: Standard Diet (SD)
Number of subjects: 438
Study 36254906 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 0
Study 36254906 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided erector spinae plane block (ESPB)
Number of subjects: 0
Study 33837987 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided strategy
Number of subjects: 172
Study 32166864 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg
Number of subjects: 14
Study 32166864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 36274185 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTv-based EMI in addition to treatment as usual (TAU)
Number of subjects: 154
Study 36274185 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 154
Study 33907787 — intervention group
Group type: EXPERIMENTAL
Intervention: Aiweizhi (experimental group)
Number of subjects: 113
Study 33907787 — intervention group
Group type: COMPARATOR
Intervention: New rehabilitation (control group)
Number of subjects: 113
Study 33907787 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 113
Study 33394323 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol treatment for 12 weeks
Number of subjects: 690
Study 34981428 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose loading
Number of subjects: 33
Study 34981428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 33
Study 33271000 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent obtained
Number of subjects: 368
Study 33271000 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific waivers for inclusion
Number of subjects: 368
Study 33271000 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to participate statement
Number of subjects: 368
Study 33271000 — intervention group
Group type: COMPARATOR
Intervention: Consent refusal rates
Number of subjects: 368
Study 35120890 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled diesel exhaust (DE) at 300 μg PM2.5/m3 for 2 hours
Number of subjects: 17
Study 35120890 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled diesel exhaust (DE) at 20, 50, or 150 μg PM2.5/m3 for 4 hours
Number of subjects: 17
Study 35120890 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled diesel exhaust (DE)
Number of subjects: 17
Study 35120890 — intervention group
Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 17
Study 35708845 — intervention group
Group type: EXPERIMENTAL
Intervention: High SBP (≥ 140 mm Hg)
Number of subjects: 2509
Study 35708845 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate SBP (140 > SBP ≥ 130 mm Hg)
Number of subjects: 2509
Study 35708845 — intervention group
Group type: COMPARATOR
Intervention: Low SBP (< 130 mm Hg)
Number of subjects: 2509
Study 34390283 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA)
Number of subjects: 75
Study 34390283 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham Acupuncture (SA)
Number of subjects: 75
Study 34390283 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 75
Study 32252963 — intervention group
Group type: EXPERIMENTAL
Intervention: TTNS sensitivity threshold (n=39)
Number of subjects: 101
Study 32252963 — intervention group
Group type: EXPERIMENTAL
Intervention: TTNS motor threshold (n=33)
Number of subjects: 101
Study 32252963 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=29)
Number of subjects: 101
Study 35051725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-gemcitabine (CG) followed by gemcitabine (G) maintenance for patients with objective response (OR) or switch to pemetrexed (P) for patients with stable disease (SD)
Number of subjects: 932
Study 35051725 — intervention group
Group type: COMPARATOR
Intervention: Control arm: 4 cycles of cisplatin-pemetrexed (CP) followed by pemetrexed (P) maintenance
Number of subjects: 932
Study 34210203 — intervention group
Group type: EXPERIMENTAL
Intervention: Flushing at 6°C
Number of subjects: 60
Study 34210203 — intervention group
Group type: EXPERIMENTAL
Intervention: Flushing at 23°C
Number of subjects: 60
Study 34210203 — intervention group
Group type: EXPERIMENTAL
Intervention: Flushing at 40°C
Number of subjects: 60
Study 33036728 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 0
Study 36101997 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutin 500 mg per day for 3 months
Number of subjects: 50
Study 36101997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 33884889 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I ≥5 ng/L
Number of subjects: 15833
Study 33884889 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP ≥100 pg/mL
Number of subjects: 15833
Study 33884889 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high-sensitivity cardiac troponin I ≥5 ng/L and BNP ≥100 pg/mL
Number of subjects: 15833
Study 33884889 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP in multivariable Cox regression model
Number of subjects: 15833
Study 33884889 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I in multivariable Cox regression model
Number of subjects: 15833
Study 36058687 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 42
Study 32050215 — intervention group
Group type: EXPERIMENTAL
Intervention: 105 nJ
Number of subjects: 62
Study 32050215 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 nJ
Number of subjects: 62
Study 32050215 — intervention group
Group type: EXPERIMENTAL
Intervention: 115 nJ
Number of subjects: 62
Study 32050215 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 nJ
Number of subjects: 62
Study 35599469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (3 times a week for 6 weeks, 60 minutes per session)
Number of subjects: 20
Study 35599469 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 34902841 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric hamstring strength training program (EHT) performed 2 days per week for 6 weeks, consisting of 5 exercises
Number of subjects: 45
Study 34902841 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 34263472 — intervention group
Group type: EXPERIMENTAL
Intervention: Edasalonexent (100 mg or 250 mg softgel capsules)
Number of subjects: 181
Study 33449508 — intervention group
Group type: EXPERIMENTAL
Intervention: DLPFC-tDCS
Number of subjects: 81
Study 33449508 — intervention group
Group type: EXPERIMENTAL
Intervention: M1-tDCS
Number of subjects: 81
Study 33449508 — intervention group
Group type: EXPERIMENTAL
Intervention: DLPFC&M1-tDCS
Number of subjects: 81
Study 33449508 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 81
Study 33449508 — intervention group
Group type: EXPERIMENTAL
Intervention: All active HD-tDCS protocols
Number of subjects: 81
Study 33637541 — intervention group
Group type: EXPERIMENTAL
Intervention: iACT intervention group
Number of subjects: 200
Study 33637541 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 200
Study 32651292 — intervention group
Group type: EXPERIMENTAL
Intervention: 200/50 mg dispersible levodopa‐benserazide (dopaminergic challenge)
Number of subjects: 76
Study 32651292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blinded, placebo-controlled dopaminergic challenge)
Number of subjects: 76
Study 32651292 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated levodopa challenge after 6 months
Number of subjects: 76
Study 36414584 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 100
Study 36414584 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 100
Study 36414584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Methotrexate and Azathioprine
Number of subjects: 100
Study 32317575 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital plasma
Number of subjects: 160
Study 32317575 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 160
Study 32317575 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypocalcemia
Number of subjects: 160
Study 616683537 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling
Number of subjects: 30
Study 616683537 — intervention group
Group type: COMPARATOR
Intervention: Microdermabrasion
Number of subjects: 30
Study 34210824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (target 110-139 mm Hg)
Number of subjects: 974
Study 34210824 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control (target 140-179 mm Hg)
Number of subjects: 974
Study 616689159 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy (specifics not provided)
Number of subjects: 30
Study 33961204 — intervention group
Group type: EXPERIMENTAL
Intervention: JiTT screencasts
Number of subjects: 67
Study 33961204 — intervention group
Group type: COMPARATOR
Intervention: Usual education curriculum
Number of subjects: 67
Study 33057184 — intervention group
Group type: EXPERIMENTAL
Intervention: Early promotion group (encouraged to visit a clinic in face-to-face interviews, provided with a referral letter and leaflet)
Number of subjects: 273
Study 33057184 — intervention group
Group type: COMPARATOR
Intervention: Control group (received usual care)
Number of subjects: 273
Study 616122532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg
Number of subjects: 24
Study 616122532 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 24
Study 616122532 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 24
Study 35942688 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium gluconate
Number of subjects: 50
Study 35942688 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride
Number of subjects: 50
Study 33967000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tampon test
Number of subjects: 10
Study 32826786 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat pars‐plana vitrectomy (PPV) and gas tamponade with ILM peel extension in 20 cases
Number of subjects: 27
Study 32826786 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat pars‐plana vitrectomy (PPV) and gas tamponade
Number of subjects: 27
Study 35285804 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraflex sirolimus-eluting stent
Number of subjects: 1435
Study 35285804 — intervention group
Group type: COMPARATOR
Intervention: XIENCE everolimus-eluting stent
Number of subjects: 1435
Study 33137486 — intervention group
Group type: EXPERIMENTAL
Intervention: MAFLD diagnosed as intrahepatic triglyceride content (IHTG) ≥5% and presence of overweight/obesity, diabetes, or two other metabolic risk factors.
Number of subjects: 1013
Study 33137486 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD diagnosed with exclusion of concomitant liver diseases; metabolic factors not considered.
Number of subjects: 1013
Study 33137486 — intervention group
Group type: EXPERIMENTAL
Intervention: MAFLD incidence.
Number of subjects: 1013
Study 33137486 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with incident NAFLD.
Number of subjects: 1013
Study 33137486 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with IHTG ≥5% but did not meet the metabolic criteria of MAFLD.
Number of subjects: 1013
Study 33137486 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular drinker with liver stiffness.
Number of subjects: 1013
Study 32434296 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hole thoracoscopic surgery with ERAS concept education and respiratory function training (Group A)
Number of subjects: 240
Study 32434296 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3-hole thoracoscopic surgery with ERAS concept education and respiratory function training (Group B)
Number of subjects: 240
Study 32434296 — intervention group
Group type: COMPARATOR
Intervention: Conventional 3-hole thoracoscopic surgery with routine hospitalization education and nursing guidance (Group C)
Number of subjects: 240
Study 32434296 — intervention group
Group type: COMPARATOR
Intervention: Single-hole thoracoscopic surgery with routine hospitalization education and nursing guidance (Group D)
Number of subjects: 240
Study 34346173 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 0
Study 34346173 — intervention group
Group type: COMPARATOR
Intervention: Surrogate outcome (time to metastasis)
Number of subjects: 0
Study 33342941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg/day)
Number of subjects: 254
Study 33342941 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 254
Study 35665787 — intervention group
Group type: EXPERIMENTAL
Intervention: h-SDS micelles
Number of subjects: 0
Study 35665787 — intervention group
Group type: EXPERIMENTAL
Intervention: d-SDS micelles
Number of subjects: 0
Study 35665787 — intervention group
Group type: EXPERIMENTAL
Intervention: h-SDS and d-SDS micelles
Number of subjects: 0
Study 34613617 — intervention group
Group type: EXPERIMENTAL
Intervention: ENABLE intervention (palliative care intervention)
Number of subjects: 529
Study 34613617 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group in ENABLE II)
Number of subjects: 529
Study 33734288 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 360
Study 33734288 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 360
Study 33734288 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study 32812041 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 469
Study 616852914 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel disposable circumcision stitching instrument
Number of subjects: 102
Study 616852914 — intervention group
Group type: COMPARATOR
Intervention: Traditional circumcision operation
Number of subjects: 102
Study 34464634 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg
Number of subjects: 41
Study 34464634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 33813324 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.90% Ca
Number of subjects: 720
Study 33813324 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35% NPP
Number of subjects: 720
Study 33813324 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.80% Ca
Number of subjects: 720
Study 33813324 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30% NPP
Number of subjects: 720
Study 33813324 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of Ca and NPP
Number of subjects: 720
Study 35770887 — intervention group
Group type: EXPERIMENTAL
Intervention: The App (Stroke Riskometer™ mobile phone application)
Number of subjects: 790
Study 35770887 — intervention group
Group type: COMPARATOR
Intervention: Usual care (generic online information about risk factors)
Number of subjects: 790
Study 35770887 — intervention group
Group type: EXPERIMENTAL
Intervention: The App
Number of subjects: 790